Last reviewed · How we verify

NCT05886010

Performance and Tolerance of Cyto-selective Difluoroethane-based Cryotherapy in th Treatment of Brown Spots (Solar and Senile Lentigines, Post-Inflammatory Hyperpigmentation) on the Face and Hands of Asian Ethnicity Skins

Status unknown NA Last updated 2 June 2023
What this trial tests

NA trial testing prototypes 1 everyday in Solar Lentigo in 120 participants. Status unknown.

Timeline
1 September 2023
Primary endpoint
29 February 2024
29 February 2024

Quick facts

Lead sponsorCryonove Pharma
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designsequential
Maskingdouble
Primary purposetreatment
Enrollment120
Start date1 September 2023
Primary completion29 February 2024
Estimated completion29 February 2024
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Cryonove Pharma

Who can join

Adults 18 to 75, any sex, with Solar Lentigo or Senile Lentigo. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

CS5\_4 study aim to evaluate the performance and the tolerance of 3 prototypes of cyto-selective cryotherapy treatments applied on the brown spots on the face and hands of asian ethnicity skins (chinese). A brown spot is defined as solar or senile lentigo (SSL) and post-inflammatory hyperpigmentation (PIH). Each treatment corresponds to a combination of a specific sequence of cryogenic spray and of a frequency of application. Each spot will be treated by a defined prototype (always the same device on the same spot all along the study). The study will evaluate the following prototype : * Prototypes 1 * Prototypes 2 * Prototypes 3

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Cryonove Pharma trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05886010.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing